Tokyo, Mar 8, 2006 (JCN) - Kyowa Hakko Kogyo has completed three phase III clinical trials for KW-6002, its investigational drug for treating Parkinson’s disease; two were conducted in North America and one in Europe. KW-6002 is a promising agent that selectively antagonizes the adenosine A2A receptor.
